Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Sponsor
Fudan University
Study ID
NCT04612894
Phase
PHASE2
Status
Unknown

Conditions

  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
14 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab and Apatinib — DRUG
    All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
  • surgery — PROCEDURE
    Perform surgery if operable after neoadjuvant therapy
  • core needle biopsy — PROCEDURE
    Perform core needle biopsy if inoperable after neoadjuvant therapy

Study Details

To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.

Key Dates

Start date
Dec 1, 2020
Status verified
Oct 2020
Primary completion
Dec 1, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
31 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant Camrelizumab + Apatinib
    Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.

Primary Outcome Measure

Objective response rate [ Time Frame: up to 24 weeks ]

Central Contacts

Related Studies